Alliance Pharmaceuticals United Kingdom

Ms Puja Thapar
Senior Manager, Corporate Development 

Alliance Pharmaceuticals Limited United Kingdom

Alliance Pharma is an internation specialty pharma busienss with a buy and build business model and asset light operations. We have a balanced portoflio of growth focussed international star brands and a cash-generative Bedrock requiring minimal promotional support. We have 20 years of operation, 35 deals experience and have been on the London stock exchange junior market (AIM) since 2003 (LSE: APH). 2017 results: £100m+ sales, 27% EBITDA, £20m+ FCF, dividend paying Our star brands are: Kelo-cote – fastest drying, silicone gel anti-scar treatment  MacuShield – exact match to the protective pigments found on the macula Vamousse – most technologically advanced treatment for head lice Nizoral – medicated anti-dandruff shampoo acquired from J&J in June 2018      
Mr Daniel Thomas
Mr Daniel Thomas
Chief Corporate Development Officer 
Mr Ben Holden
Business Insights Analyst 

Altacor United Kingdom

Mr Nelson Fernandes
Affiliate Manager 

Aspire Pharma Ltd United Kingdom

Mr Graham Fraser-Pye
Managing Director 

ChilversMcCrea Healthcare United Kingdom

Dr Rory McCrea

Chugai Pharma Europe Ltd. United Kingdom

Chugai Pharma Europe Ltd. is seeking for in-licensing and partnering opportunities for its European key territories in UK, Germany and France. We strive to build our business model on existing partnerships in oncology/hematology and rheumatology as well as to grow as a organization with strong commercialization expertise, broad market access and pricing knowledge and valuable experience in medical advocacy and KOL Management.

We look forward to meeting you in Montreux,

Ryo ishimura and Florian Streckert 

Mr Florian Streckert
Mr Florian Streckert
Business Development Manager 
Mr Ryo Ishimura
Mr Ryo Ishimura
Marketing Manager 

Circassia Pharmaceuticals United Kingdom

Circassia: specialty respiratory pharmaceutical and medical device company

Circassia is building a world-class, specialty pharmaceutical and medical device company focused on respiratory disease and we have our own direct sales and support infrastructure in US, UK and Germany, and we are expanding our team in China where we expect to have 90 people in place by the end of 2018.

We have a collaboration with AstraZeneca in the US to market Tudorza (aclinidium DPI) for COPD and expect to launch Duaklir (aclidinium/formoterol DPI) in 2019, following the recent filing with FDA.  We also market our own NIOX asthma management devices in 35 markets, either via our own sales teams or distributors.


In-licensing or acquisition targets

We are actively looking for new pharmaceutical products/devices in US, China and Europe.  Our targets are late stage or marketed products that are either in respiratory or allied fields, or which can be supported by a small focused sales team.  We would also consider products that share a common physician call point.

Out licensing opportunities

We are also looking for partners who we can work with to progress our development pipeline that comprises direct substitutes for leading asthma and COPD products, as well as a number of treatments based on novel formulations of currently approved drugs.

Circassia is highly responsive and flexible and is open to a wide range of deal structures from promotion deals through licensing to acqusition.

Arnold Busmic
Arnold Busmic
Corporate Business Development Manager 
John Buckle
John Buckle
Business Development Director 

Concordia International United Kingdom

Ms Olivia Ceulemans
Senior Business Development Manager 
Mr Jujhar Chima
Business Development Alliance Managers 

Consilient Health United Kingdom

Ms Jeanette Evans
Chief Business Development Officer 

EGAMID LTD United Kingdom